scholarly journals Coexistence of follicular lymphoma and an unclassifiable myeloproliferative neoplasm in a treatment-naïve patient: A case report

2015 ◽  
Vol 11 (2) ◽  
pp. 1469-1473
Author(s):  
GYEONGMIN JEONG ◽  
JINHYONG KIM ◽  
SEEUN HAN ◽  
JONGMIN LEE ◽  
KYUNGHYE PARK ◽  
...  
Keyword(s):  
Case Report ◽  
Follicular Lymphoma ◽  
Myeloproliferative Neoplasm ◽  
Naive Patient ◽  
Treatment Naïve

HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report

2020 ◽  
Vol 36 (4) ◽  
pp. 256-257 ◽  
Author(s):  
Arturo Ciccullo ◽  
Gianmaria Baldin ◽  
Francesca Lombardi ◽  
Alberto Borghetti ◽  
Simona Di Giambenedetto
Keyword(s):  
Case Report ◽  
Integrase Inhibitors ◽  
Resistance Mutations ◽  
Naive Patient ◽  
Hiv Dna ◽  
Treatment Naïve

scholarly journals Management of myelofibrosis during pregnancy: A case report

2015 ◽  
Vol 72 (4) ◽  
pp. 383-385 ◽  
Author(s):  
Radmila Zivkovic ◽  
Olivera Markovic ◽  
Dragomir Marisavljevic ◽  
Tatjana Terzic ◽  
Ljiljana Tukic
Keyword(s):  
Case Report ◽  
Myeloproliferative Neoplasm ◽  
Primary Myelofibrosis ◽  
Normal Pregnancy ◽  
Hematologic Malignancies ◽  
Low Molecular Weight ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Pregnancy And Delivery ◽  
Normal Baby

Introduction. Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm that occurs most commonly in the decade six of life and it is very rare in the young persons. Case report. We reported a 28-year-old female patient with primary myelofibrosis who had a normal pregnancy and delivery in the week 40 of pregnancy without any complications. Two years before the diagnosis of PMF she had normal pregnancy. The patient was treated with interferon-alpha and low dose aspirin during the whole pregnancy and with low-molecular-weight heparin a week before delivery and 6 weeks after. The patient had no complications during pregnancy. She delivered in term with healthy, normal baby weight. Conclusion. Decision about treatment strategy of pregnancy associated hematologic malignancies should be made for each patient individually.

Follicular Lymphoma With a Burkitt Translocation—Predictor of an Aggressive Clinical Course: A Case Report and Review of the Literature

2004 ◽  
Vol 128 (2) ◽  
pp. 210-213 ◽  
Author(s):  
Peter M. Voorhees ◽  
Kathryn A. Carder ◽  
Scott V. Smith ◽  
Lanier H. Ayscue ◽  
Kathleen W. Rao ◽  
...  
Keyword(s):  
Case Report ◽  
Follicular Lymphoma ◽  
Clinical Course ◽  
Lymphoblastic Leukemia ◽  
Initial Diagnosis ◽  
Indolent Lymphoma ◽  
Review Of The Literature ◽  
Cell Type ◽  
Aberrant Expression ◽  
Aggressive Clinical Course

Abstract Follicular lymphoma is an indolent lymphoma characterized by the (14;18) translocation, which leads to aberrant expression of Bcl-2. Translocations involving 8q24 are most commonly associated with Burkitt lymphoma and result in c-Myc overexpression. We report a case of follicular lymphoma of predominant small cleaved-cell type (grade 1) associated with both a t(14;18)(q32;q21) and a t(8;22)(q24;q11). The 8q24 translocation predicted an aggressive clinical course, as the lymphoma transformed into acute lymphoblastic leukemia within a year of initial diagnosis. Routine cytogenetic analysis is recommended at initial diagnosis of follicular lymphoma to better identify abnormalities that may predict prognosis and influence therapy.

scholarly journals Case Report: Emergent Resistance in a Treatment-Naïve Person with HIV under Bictegravir-based Therapy"

2021 ◽  
Author(s):  
Nicholas Chamberlain ◽  
Leandro Mena ◽  
James Benjamin Brock
Keyword(s):  
Case Report ◽  
Treatment Naïve

Abstract Few instances of treatment-emergent resistance to bictegravir have been reported in the literature. We describe a case of treatment-emergent resistance to bictegravir in a person recently diagnosed with HIV who developed M184V and R263K mutations while on therapy.

scholarly journals Retrospective, observational study on usage of evogliptin in T2DM patients: A real-World experience in Indian patients

2021 ◽  
Vol 8 (3) ◽  
pp. 205-207
Author(s):  
Abhijit Trailokya ◽  
Amol Aiwale ◽  
Roshan Pawar ◽  
Suhas Erande
Keyword(s):  
Real World ◽  
Small Sample Size ◽  
Small Sample ◽  
Hypoglycemic Agents ◽  
P Value ◽  
Base Line ◽  
Oral Hypoglycemic Agents ◽  
Naive Patient ◽  
Indian Patients ◽  
Treatment Naïve

This study aimed to assess effectiveness and safety of Evogliptin 5 mg in patients with T2DM who were prescribed Evogliptin alone or with other oral hypoglycemic agents in real world scenario. Overall 20 patients who received Evogliptin as routine clinical practice in management of T2DM were analyzed retrospectively from single center. Data collected from past medical records. Primary endpoint was mean changes in HbA1c from baseline to weeks 24 and secondary endpoints were Change in HbA1c from baseline to weeks 12 Change from baseline in FPG & PPG at weeks 12 & 24.Significant reduction in HbA1c at the end of 12 and 24 weeks of Evogliptin therapy was - 0.9% and -1.45% respectively from the baseline of HbA1c 8.6% (p value <0.001). At the end of 12 and 24 weeks of addition of Evogliptin, significant reduction in FBG were seen i.e -49.5 mg/dl and -90.7mg/dl respectively from base line of 182 mg/dl and reduction in PPG was -79.4mg/dl and -116.6mg/dl respectively from base line 277 mg/dl (p value <0.001). Evogliptin was found to be effective when added to the patients who were uncontrolled on dual / triple oral anti-diabetic medications and even in treatment naïve patient. It effectively showed reduction in HbA1c, FBG and PPG and the end of 12 and 24 weeks when added to existing anti-diabetic medications & well tolerated in type 2 diabetes Indian patients.Small sample size and retrospective study

Sign in / Sign up

Export Citation Format

Share Document